[{"orgOrder":0,"company":"Q BioMed","sponsor":"Clionix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2021","type":"Licensing Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Clionix","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Clionix"},{"orgOrder":0,"company":"Q BioMed","sponsor":"isoSolutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2021","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ isoSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ isoSolutions"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Chengdu Syncor Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2022","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Chengdu Syncor Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Chengdu Syncor Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals for Strontium-89 Chloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The agreement is expected to be a high-growth opportunity to supply Strontium89 in the Chinese market. Strontium89 is FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic...

                          Product Name : Metastron

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Undisclosed

                          July 03, 2022

                          Lead Product(s) : Strontium-89 Chloride

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Chengdu Syncor Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait & Pakistan.

                          Product Name : Metastron

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Undisclosed

                          December 07, 2021

                          Lead Product(s) : Strontium-89 Chloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Clionix

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.

                          Product Name : Metastron

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Undisclosed

                          October 08, 2021

                          Lead Product(s) : Strontium-89 Chloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : isoSolutions

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          X-pert Med GmbH

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          X-pert Med GmbH

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 23, 2011

                          Lead Product(s) : Strontium-89 Chloride

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank